Stuart Kupfer
University of Connecticut
28 Papers
88 Citations
Stuart Kupfer is an academic researcher from University of Connecticut. The author has contributed to research in topics: Azilsartan Medoxomil & Coronary artery disease. The author has an hindex of 11, co-authored 28 publications. Previous affiliations of Stuart Kupfer include Abbott Laboratories.
Chat about Author
Papers
Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?
Franz H. Messerli,Giuseppe Mancia,C. Richard Conti,Ann C. Hewkin,Stuart Kupfer,Annette Champion,R. Kolloch,Athanase Benetos,Carl J. Pepine +8 more
TL;DR: A secondary analysis of data from a large trial of 2 antihypertensive drug regimens in patients with known coronary artery disease found a J-shaped relationship between diastolic blood pressure and all-cause death and myocardial infarction.
794
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
George L. Bakris,Domenic A. Sica,Michael Weber,William B. White,Andrew V. Roberts,Alfonso Perez,Charlie Cao,Stuart Kupfer +7 more
TL;DR: AZL‐M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM‐M, and the side effect profiles of both ARBs were similar to placebo.
147
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
John R. Teerlink,Rafael Diaz,G. Michael Felker,John J.V. McMurray,Marco Metra,Scott D. Solomon,Tor Biering-Sørensen,Michael Böhm,Diana Bonderman,James C. Fang,David E Lanfear,M. Lund,Shin-ichi Momomura,Eileen O'Meara,Piotr Ponikowski,Jindrich Spinar,Jose H. Flores-Arredondo,Brian Claggett,Stephen B. Heitner,Stuart Kupfer,Siddique Abbasi,Fady I. Malik,Galactic-Hf Investigators +22 more
TL;DR: GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, omecamtiv mecar...
90
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
G. Michael Felker,G. Michael Felker,G. Michael Felker,Scott D. Solomon,Brian Claggett,Rafael Diaz,John J.V. McMurray,Marco Metra,Inder S. Anand,Marisa G. Crespo-Leiro,Ulf Dahlström,Eva Goncalvesova,Jonathan G. Howlett,Peter S. Macdonald,Alexander Parkhomenko,János Tomcsányi,Siddique Abbasi,Stephen B. Heitner,Thomas Hucko,Stuart Kupfer,Fady I. Malik,John R. Teerlink,John R. Teerlink +22 more
TL;DR: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) randomized clinical trial as mentioned in this paper evaluated the efficacy and safety of omecamtiv mecarbil for the treatment of patients with severe heart failure.
83
Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease
Carl J. Pepine,Peter R. Kowey,Stuart Kupfer,R. Kolloch,Athanase Benetos,Giuseppe Mancia,Antonio Coca,Rhonda M. Cooper-DeHoff,Eileen M. Handberg,Efrain Gaxiola,Peter Sleight,C. Richard Conti,Ann C. Hewkin,Luigi Tavazzi,Invest Investigators +14 more
TL;DR: In hypertensive patients with CAD, increased risk for adverse outcomes was associated with conditions related to the severity of CAD and diminished left ventricular function, and lower follow-up BP and addition of trandolapril to verapamil SR each were associated with reduced risk.
61